Biocidal Product Registration under the BPR
Placing a biocidal product on the European Union market requires prior authorisation and a strategy consistent with Regulation (EU) No 528/2012.
SHAPYPRO provides technical and regulatory support to analyse the product, identify the Product Type, review active substance status, define the authorisation route and coordinate the documentation required for a consistent dossier.
- BPR · Regulation (EU) 528/2012
- Active substances
- IUCLID dossier
- R4BP 3
Biocidal Product Registration with a Structured Regulatory Approach
Biocidal product authorisation is not simply a matter of submitting a dossier. Before the procedure begins, the regulatory nature of the product, its composition, intended uses, target organisms, application conditions and target markets must be confirmed.
A poorly defined strategy can lead to studies that do not support the intended use, inconsistencies between the dossier and label, requests for additional information or delays during evaluation.
SHAPYPRO assesses the starting point and proposes a proportionate roadmap connecting regulatory requirements, efficacy evidence, technical documentation and commercial objectives.
Active Substances and Suppliers
Review of active substance approval for the relevant Product Type and verification of the supplier’s Article 95 status where applicable.
Product Type and Intended Uses
Identification of the PT, target organisms, users, application areas and use conditions that determine the data requirements.
Efficacy and Claims
Assessment of consistency between proposed claims, test methods, experimental conditions and the instructions of use to be included in the authorisation.
Risk and Documentary Consistency
Coordination of the information required so that composition, risk assessment, classification, labelling, Safety Data Sheet and dossier describe the same product.
Classification, Product Types and Active Substances
The first step is to confirm that the product falls within the scope of the BPR. A biocidal product contains, generates or incorporates one or more active substances with the intention of controlling harmful organisms by means other than mere physical or mechanical action.
The Regulation covers 22 Product Types grouped into disinfectants, preservatives, pest control products and other specialised biocidal products. Correct classification determines the regulatory status of the active substance, efficacy testing and the authorisation route.
Product Classification
Analysis of the primary purpose, mode of action, presentation and claims to determine whether the item is a biocidal product, a treated article or another regulated product.
Product Type · PT Identification
Definition of the PT or combination of PTs applicable to the intended uses and harmful organisms to be controlled.
Active Substance Status
Verification of whether the substance is approved, included in Annex I or under the Review Programme for the relevant PT.
Article 95 List
Verification that the substance or product supplier is listed for the relevant active substance and Product Type combination.
Transitional Situations
Review of possible national transitional regimes where a decision on an active substance included in the Review Programme has not yet been adopted.
Support Services for Biocidal Product Authorisation
The scope is adapted to the project stage, product profile, available documentation and countries in which market access is planned.
Support may cover a specific review or technical-regulatory assistance throughout preparation and processing of the application.
Initial Regulatory Diagnosis
Review of composition, uses, classification, target markets and available documentation to identify requirements, risks and gaps.
Authorisation Strategy
Definition of the most appropriate route, including national authorisation, mutual recognition, Union authorisation, simplified authorisation or same biocidal product procedures.
Study Review and Testing Plan
Assessment of existing evidence and definition of additional needs relating to efficacy, physicochemical properties, stability, human health or the environment.
Dossier Preparation and Review
Organisation of technical and administrative information, consistency review and identification of missing data before submission.
Summary of Product Characteristics · SPC
Preparation or review of the document describing authorised uses, doses, contact times, target organisms, users, instructions and risk-management measures.
Labelling, Claims and Safety Data Sheet
Review of alignment between the requested authorisation, CLP classification, label, advertising and safety documentation.
Submission and Follow-Up
Support with application preparation, document upload and technical responses to authority observations or requests for additional information.
Changes, Renewals and Maintenance
Review of subsequent changes, use extensions, administrative amendments, renewals and obligations during the authorisation period.
A strategy defined before testing and dossier preparation helps reduce duplication, identify gaps and maintain consistency between the real product, the evidence and the requested authorisation.
Authorisation Routes under the BPR
The applicable route depends on the product, the Member States of interest, the status of the active substances and the company’s market strategy.
Not every procedure is available for every product. Eligibility should be assessed before planning the dossier and selecting the evaluating authority.
National Authorisation
Procedure for placing the product on the market in one Member State. It may later serve as the basis for extending the authorisation to other countries.
Mutual Recognition
Extension of a national authorisation to other Member States through mutual recognition in sequence or in parallel.
Union Authorisation
Authorisation valid across EU Member States for eligible products with similar conditions of use throughout the Union.
Simplified Authorisation
Procedure reserved for products meeting all specific BPR conditions, including the use of Annex I active substances and the absence of defined concern characteristics.
Same Biocidal Product
Procedure available where the product is identical to an authorised biocidal product or to a product for which an application is under evaluation, subject to the applicable conditions.
Biocidal Product Family
A strategy that may group products with similar uses and defined composition variations where the regulatory criteria are met.
Dossier, IUCLID, SPC and R4BP 3
BPR applications are managed using specific tools and formats. IUCLID is used to structure and store technical information, while R4BP 3 is the submission and communication platform used by ECHA and competent authorities.
The exact content depends on the product and selected route. The dossier must be organised, traceable and capable of supporting the proposed uses and conclusions.
Identity and Composition
Qualitative and quantitative information, substance identities, relevant impurities, specifications and links to the tested materials.
Manufacture and Product Properties
Manufacturing method, physicochemical properties, stability, packaging compatibility and relevant analytical methods.
Uses and Efficacy Data
Target organisms, use areas, users, doses, concentrations, contact times, application conditions and evidence supporting each claim.
Human Health, Animal Health and Environment
Data and assessments required to characterise exposure and risks associated with the proposed uses.
Classification, Labelling and Safety
Proposed classification and labelling, risk-management measures, instructions of use, Safety Data Sheet and packaging requirements.
SPC and Administrative Documentation
Summary of Product Characteristics, forms, letters of access, data references and the required corporate or administrative documentation.
Efficacy, Claims, Labelling and Documentary Consistency
Efficacy must be demonstrated for the uses and claims for which authorisation is sought. Studies should adequately represent the product, target organisms and real conditions of use.
Concentration, contact time, temperature, soiling, surface, application method and user category can affect the interpretation of results.
The dossier, SPC, label, Safety Data Sheet and commercial communication must remain aligned. A claim that is not supported by the evidence or requires conditions different from those assessed may compromise the application.
Organisms and Spectrum of Activity
Verification that the tested microorganisms or pests support the proposed claims.
Conditions of Use
Consistency between studies, dose, contact time, dilution, application method and the instructions provided to users.
Tested Product
Confirmation that the formulation, active substance concentration and product characteristics assessed represent the product to be authorised.
Label and Advertising
Review to ensure that commercial messages do not extend the scope of the authorisation or present the product in a misleading manner.
CLP, SDS and SPC
Alignment of classification, precautions, risk-management measures and instructions across all product documents.
Working Methodology
Each project is organised according to its development stage, active substance status, available evidence and target markets.
SHAPYPRO coordinates the work so that regulatory decisions are taken before documentation or studies are generated that may later prove insufficient or unnecessary.
Initial Review
Analysis of the product, composition, suppliers, uses, PTs, countries of interest and existing documentation.
Requirements Map and GAP Analysis
Identification of the regulatory route, available data, gaps and decisions to be resolved before preparing the application.
Technical and Documentary Plan
Definition of studies, assessments, documents, responsibilities and work sequence.
Dossier Preparation and Control
Coordination of the dossier, cross-checking of data and verification of consistency between IUCLID, SPC, label and annexes.
Submission and Follow-Up
Support during processing, management of observations and update of documents when authorities request clarification.
Post-Authorisation Maintenance
Support with changes, renewals, extensions, communication obligations and review of new relevant information.
Frequent Issues that Delay Authorisation
Many issues originate before the application is submitted. Identifying them during the strategy stage helps avoid late corrections and provides better control over time and cost.
Incorrectly Defined PT or Use
Classification does not reflect all intended uses or includes claims requiring another Product Type.
Active Substance or Supplier Not Verified
Approval for the relevant PT, transitional status or Article 95 listing has not been checked.
Insufficient Efficacy Studies
Studies do not cover all organisms, conditions, concentrations or contact times included in the claims.
Non-Representative Tested Product
The formulation or test conditions do not match the product intended for the market.
Inconsistencies between Documents
The dossier, SPC, label, SDS and advertising describe different uses, precautions or conditions.
Late Planning of Risk and Data Requirements
Human-health, environmental or exposure data needs are identified only when the dossier is already advanced.
Regulatory Support Adapted to Each Biocidal Product
Each biocidal product has a different combination of active substances, uses, target organisms, users, application conditions and target markets.
SHAPYPRO adapts the scope to the starting point of each project, providing technical review, documentary coordination and regulatory guidance to prepare a stronger and more consistent application.
